Bispecific FpFs: a versatile tool for preclinical antibody development

Article


Collins, M., Ibeanu, N., Grabowska, W. R., Awwad, S., Khaw, P. T., Brocchini, S. and Khalili, H. 2024. Bispecific FpFs: a versatile tool for preclinical antibody development. RSC Chemical Biology. 5, pp. 1147-1164. https://doi.org/10.1039/D4CB00130C
AuthorsCollins, M., Ibeanu, N., Grabowska, W. R., Awwad, S., Khaw, P. T., Brocchini, S. and Khalili, H.
Abstract

We previously described FpFs [1 with combining low line] (Fab–PEG–Fab) as binding mimetics of IgGs. FpFs are prepared with di(bis-sulfone) conjugation reagents [3 with combining low line] that undergo disulfide rebridging conjugation with the accessible disulfide of each Fab (Scheme 1). We have now prepared bispecific FpFs [2 with combining low line] (bsFpF and Fab1–PEG–Fab2) as potential bispecific antibody mimetics with the intent that bsFpFs could be used in preclinical antibody development since sourcing bispecific antibodies may be challenging during preclinical research. The di(bis-sulfone) reagent [3 with combining low line] was first used to prepare a bsFpF [2 with combining low line] by the sequential conjugation of a first Fab and then a second Fab to another target (Scheme 2). Seeking to improve bsFpF synthesis, the asymmetric conjugation reagent, bis-sulfone bis-sulfide [1 with combining low line][6 with combining low line], with different thiol conjugation reactivities at each terminus (Scheme 4) was examined and the bsFpFs appeared to be formed at similar conversion to the di(bis-sulfone) reagent [3 with combining low line]. To explore the advantages of using common intermediates in the preparation of bsFpF families, we investigated bsFpF synthesis with a protein conjugation–ligation approach (Scheme 5). Reagents with a bis-sulfone moiety for conjugation on one PEG terminus and a ligation moiety on the other terminus were examined. Bis-sulfone PEG trans-cyclooctene (TCO) [2 with combining low line][8 with combining low line] and bis-sulfone PEG tetrazine (Tz) [3 with combining low line][0 with combining low line] were used to prepare several bsFpFs targeting various therapeutic targets (TNF-α, IL6R, IL17, and VEGF) and tissue affinity targets (hyaluronic acid and collagen II). Surface plasmon resonance (SPR) binding studies indicated that there was little difference between the dissociation rate constant (kd) for the unmodified Fab, mono-conjugated PEG–Fab and the corresponding Fab in a bsFpF. The Fab association rate (ka) in the bsFpF was slower than for PEG–Fab, which may be because of mass differences that influence SPR results. These observations suggest that each Fab will bind to its target independently of the other Fab and that bsFpF binding profiles can be estimated using the corresponding PEG–Fab conjugates.

JournalRSC Chemical Biology
Journal citation5, pp. 1147-1164
ISSN2633-0679
Year2024
PublisherRoyal Society of Chemistry
Publisher's version
License
File Access Level
Anyone
Digital Object Identifier (DOI)https://doi.org/10.1039/D4CB00130C
Publication dates
Online27 Sep 2024
Publication process dates
Accepted08 Sep 2024
Deposited06 Feb 2025
Copyright holder© 2024 The Authors
Permalink -

https://repository.uel.ac.uk/item/8yz9v

Download files


Publisher's version
d4cb00130c.pdf
License: CC BY-NC 4.0
File access level: Anyone

  • 9
    total views
  • 3
    total downloads
  • 9
    views this month
  • 3
    downloads this month

Export as

Related outputs

Development of bispecific antibody mimetics
Collins, M. 2024. Development of bispecific antibody mimetics. PhD Thesis University of East London School of Health, Sports & Bioscience
Soluble Papain to Digest Monoclonal Antibodies; Time and Cost-Effective Method to Obtain Fab Fragment
Collins, M. and Khalili, H. 2022. Soluble Papain to Digest Monoclonal Antibodies; Time and Cost-Effective Method to Obtain Fab Fragment. Bioengineering. 9 (Art. 209). https://doi.org/10.3390/bioengineering9050209
Dual acting therapeutic proteins for intraocular use
Collins, M., Awwad, S., Ibeanu, N., Khaw, P. T., Guiliano, D., Brocchini, S. and Khalili, H. 2020. Dual acting therapeutic proteins for intraocular use. Drug Discovery Today. 26 (1), pp. 44-55. https://doi.org/10.1016/j.drudis.2020.10.025